山东药玻最新公告：鲁中投资重组事宜终止公司拟向特定对象发行股份引入国药国际作为控股股东

证券之星01-13

山东药玻(600529.SH)公告称，公司收到鲁中投资通知，由于市场环境变化，经各方友好协商，决定终止鲁中投资重组事宜。同时，公司拟向特定对象发行股份，由国药国际及其实控的山东耀新全额认购，发行完成后，国药国际将成为公司控股股东，国药集团将成为公司实际控制人。此次发行旨在进一步提升公司综合竞争力，实现高质量发展。

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603682447?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-13 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603682447","market":"fut","top_or_hot":-1,"title":"山东药玻最新公告：鲁中投资重组事宜终止公司拟向特定对象发行股份引入国药国际作为控股股东","media":"证券之星","content":"<html><body><p><a href=\"https://laohu8.com/S/600529\">山东药玻</a>(600529.SH)公告称，公司收到鲁中投资通知，由于市场环境变化，经各方友好协商，决定终止鲁中投资重组事宜。同时，公司拟向特定对象发行股份，由<a href=\"https://laohu8.com/S/600511\">国药</a>国际及其实控的山东耀新全额认购，发行完成后，<a href=\"https://laohu8.com/S/08156\">国药</a>国际将成为公司控股股东，国药集团将成为公司实际控制人。此次发行旨在进一步提升公司综合竞争力，实现高质量发展。</p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>山东药玻最新公告：鲁中投资重组事宜终止公司拟向特定对象发行股份引入国药国际作为控股股东</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n山东药玻最新公告：鲁中投资重组事宜终止公司拟向特定对象发行股份引入国药国际作为控股股东\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-13 21:38 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026011300041308.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>山东药玻(600529.SH)公告称，公司收到鲁中投资通知，由于市场环境变化，经各方友好协商，决定终止鲁中投资重组事宜。同时，公司拟向特定对象发行股份，由国药国际及其实控的山东耀新全额认购，发行完成后，国药国际将成为公司控股股东，国药集团将成为公司实际控制人。此次发行旨在进一步提升公司综合竞争力，实现高质量发展。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026011300041308.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0186","symbol_name":"小盘成长","start_time":0,"source_url":"https://stock.stockstar.com/RB2026011300041308.shtml","article_id":"2603682447","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603682447","pubTimestamp":1768311512,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"山东药玻(600529.SH)公告称，公司收到鲁中投资通知，由于市场环境变化，经各方友好协商，决定终止鲁中投资重组事宜。同时，公司拟向特定对象发行股份，由国药国际及其实控的山东耀新全额认购，发行完成后，国药国际将成为公司控股股东，国药集团将成为公司实际控制人。此次发行旨在进一步提升公司综合竞争力，实现高质量发展。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600529":"山东药玻","BK0186":"小盘成长","BK0235":"非金矿物"},"translate_title":"The latest announcement of Shandong Pharmaceutical Glass: The restructuring of Luzhong Investment has been terminated. The company plans to issue shares to specific objects and introduce Sinopharm International as the controlling shareholder","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600529":1.5},"content_text":"山东药玻(600529.SH)公告称，公司收到鲁中投资通知，由于市场环境变化，经各方友好协商，决定终止鲁中投资重组事宜。同时，公司拟向特定对象发行股份，由国药国际及其实控的山东耀新全额认购，发行完成后，国药国际将成为公司控股股东，国药集团将成为公司实际控制人。此次发行旨在进一步提升公司综合竞争力，实现高质量发展。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603682447","isCrawlerRequest":true}